Drug Profile
Calcium succinate - BioLink Life Sciences
Alternative Names: PhosvedaLatest Information Update: 15 Mar 2019
Price :
$50
*
At a glance
- Originator BioLink Life Sciences
- Class Small molecules
- Mechanism of Action Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hyperphosphataemia
Highest Development Phases
- No development reported Hyperphosphataemia
Most Recent Events
- 15 Mar 2019 No recent reports of development identified for preregistration for Hyperphosphataemia in USA (PO)
- 12 Aug 2016 Chemical structure information added
- 03 Aug 2016 Preregistration is ongoing in USA